The hybrid closed-loop insulin delivery system serves as the world's first synthetic (artificial) pancreas. The hybrid closed-loop insulin delivery system will help the type I diabetes patients in controlling their insulin quantity in the body. This was approved in late 2017 by the Food and Drug Administration (FDA), which owns a neotechnology that enables to have a direct link between the device and insulin pump to even out blood glucose at an exceptional level. This technology switches the “open loop” system that needs patients to access their own information to calculate how much insulin has to be injected. Many type I diabetes mellitus (DM) patients demand this technology in 2019. Many experts also predict that a similar technology will hit community soon for the type II diabetes patients.